^
    Back
    Association details:
    Biomarker:GZMB R43Q
    Cancer:Non Small Cell Lung Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Immunother Cancer
    Title:

    Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer

    Published date:
    05/26/2020
    Excerpt:
    Patients with homozygous and heterozygous variants of GZMB rs8192917 had worse BOR (OR: 1.60; 95% CI: 1.01 to 2.52; p=0.044) and worse PFS (HR: 1.38; 95% CI:1.02 to 1.87; p=0.036) than wild types….A low baseline serum level of granzyme B and germline variation of GZMB was associated with worse clinical outcome in NSCLC...
    DOI:
    10.1136/jitc-2020-000586